Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 1000iu/vial - moroctocog alfa (af-cc) 1000iu/vial

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 2000iu/vial - moroctocog alfa (af-cc) 2000iu/vial

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 250iu/vial - moroctocog alfa (af-cc) 250iu/vial

Singapore - engelsk - HSA (Health Sciences Authority)

pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 500iu/vial - moroctocog alfa (af-cc) 500iu/vial

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - octocog alfa; recombinant coagulation factor viii -

USA - engelsk - NLM (National Library of Medicine)

csl behring llc - antihemophilic factor human (unii: 839moz74gk) (antihemophilic factor human - unii:839moz74gk) - antihemophilic factor human 250 [iu] in 2.5 ml - monoclate-p® is indicated for treatment of classical hemophilia (hemophilia a). affected individuals frequently require therapy following minor accidents. surgery, when required in such individuals, must be preceded by temporary corrections of the clotting abnormality. surgical prophylaxis in severe ahf deficiency can be accomplished with an appropriately-dosed pre-surgical iv bolus of monoclate-p® followed by intermittent maintenance doses (see dosage and administration ). monoclate-p® is not effective in controlling the bleeding of patients with von willebrand's disease. known hypersensitivity to mouse protein is a contraindication to monoclate-p® .